Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2

Table 2

Pathway analysis using the PG2-enriched signature (top 30 pathways).

Pathway	Source	#Genes in set	value	-value	Overlap	Immune	cancer
Immune system	Reactome	1011			28	□
Pathways in cancer	KEGG	327			15		□
NF-kappa B signaling pathway	KEGG	92			9	□	□
Hepatitis C	KEGG	133			10
Cytokine signaling in immune system	Reactome	186			11	□
Signaling events mediated by stem cell factor receptor (c-Kit)	PID	53			7	□	□
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways	Reactome	53			7	□
IL2 signaling events mediated by STAT5	PID	32			6	□	□
EPO signaling pathway	PID	34			6	□
Epstein-Barr virus infection	KEGG	204			11
Neurotrophic factor-mediated Trk receptor signaling	PID	65			7	□
Measles	KEGG	134			9	□
TRAF3-dependent IRF activation pathway	Reactome	13			4		□
Signaling events mediated by hepatocyte growth factor receptor (c-Met)	PID	84			7		□
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon	Reactome	15			4	□	□
MyD88-independent cascade	Reactome	97			7	□
Toll-like receptor 3 (TLR3) cascade	Reactome	97			7	□	□
Beta-catenin phosphorylation cascade	Reactome	17			4	□	□
Platelet sensitization by LDL	Reactome	18			4	□
Interferon signaling	Reactome	69			6	□	□
Signaling events mediated by TCPTP	PID	41			5	□	□
RIG-I-like receptor signaling pathway	KEGG	71			6	□	□
Chronic myeloid leukemia	KEGG	73			6	□	□
Activated TLR4 signaling	Reactome	111			7	□	□
Negative regulators of RIG-I/MDA5 signaling	Reactome	21			4
Signaling by interleukins	Reactome	114			7	□	□
Inhibition of cellular proliferation by Gleevec	PID	22			4	□	□
Interleukin-3, interleukin-5, and GM-CSF signaling	Reactome	47			5	□
CTLA4 inhibitory signaling	Reactome	23			4	□
Neurotrophin signaling pathway	KEGG	120			7